AMT announces successful treatment of DMD with gene therapy
Do you know when to trade AMLRF ?
AMLRF | Quote | Chart | News | PowerRating -- Human gene therapy company Amsterdam Molecular Therapeutics (AMT)
(Euronext: AMT) announced today that it has successfully treated
Duchenne muscular dystrophy (DMD) in an animal model with its
proprietary gene therapy.
The company said that the proof of concept studies were performed in
collaboration with the group of Professor Irene Bozzoni, University of
Rome, La Sapienza, Italy, and demonstrated effectiveness in the heart
as well as in skeletal muscles.
In a previous study, AMT's gene therapy approach was shown to be
successful in the treatment of diseased human muscle cells obtained
from biopsies of DMD patients.
These data reportedly establish a robust basis for AMT's therapeutic
approach to DMD.
Comments on this story may be sent to admin@m2.com
For full details on (AMLRF) AMLRF. (AMLRF) has Short Term PowerRatings at TradingMarkets. Details on (AMLRF) Short Term PowerRatings is available at This Link.
- AMT initiates dosing in Phase I/II hemophilia trial - 03/11/10
- Amsterdam Molecular Therapeutics reports start of Phase I/II gene therapy clinical trial for haemophilia B - 03/10/10
- AMT starts Phase I/II gene therapy clinical trial for Haemophilia B - 03/10/10
- Amsterdam Molecular Therapeutics: Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B - 03/10/10
- Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B - 03/10/10
- More News >>


